Menu
July 19, 2019  |  

Characterizing and overriding the structural mechanism of the Quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397.

Authors: Smith, Catherine C and Zhang, Chao and Lin, Kimberly C and Lasater, Elisabeth A and Zhang, Ying and Massi, Evan and Damon, Lauren E and Pendleton, Matthew and Bashir, Ali and Sebra, Robert and Perl, Alexander and Kasarskis, Andrew and Shellooe, Rafe and Tsang, Garson and Carias, Heidi and Powell, Ben and Burton, Elizabeth A and Matusow, Bernice and Zhang, Jiazhong and Spevak, Wayne and Ibrahim, Prabha N and Le, Mai H and Hsu, Henry H and Habets, Gaston and West, Brian L and Bollag, Gideon and Shah, Neil P

Tyrosine kinase domain mutations are a common cause of acquired clinical resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib. Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance. The molecular underpinnings of gatekeeper mutation-mediated resistance are incompletely understood. We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face aromatic interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop. This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere. Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation. PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop. Cancer Discov; 5(6); 668-79. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 565. ©2015 American Association for Cancer Research.

Journal: Cancer discovery
DOI: 10.1158/2159-8290.CD-15-0060
Year: 2015

Read Publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.